Phase N/AAssessment of Bimodal Stimulation Device [Lenire] Compliance and Satisfaction in Individuals With Tinnitus
NewsIn Case You Missed It: Tinnitus Hub Director Hazel Goedhart gives us the cold, hard, unbiased facts about Lenire…
NewsNeuromod Successfully Closes $12.4 Million Series B Financing for Tinnitus Treatment Device Lenire®
ResearchBimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study
NewsNew Treatment Alleviates Ringing in the Ears: A noninvasive device [Lenire] designed to rewire brain circuits reduced symptoms of tinnitus in a large clinical trial
NewsStudy findings demonstrate that Lenire (Neuromod) for tinnitus “provides safe, fast-acting (within 6 weeks) and reproducible therapeutic effects that can last at least 12 months.”
ResearchNoninvasive Bimodal Neuromodulation for the Treatment of Tinnitus: Protocol for a Second Large-Scale Double-Blind Randomized Clinical Trial to Optimize Stimulation Parameters
NewsNeuromod Successfully Closes €8 Million Capital Raise: proceeds will be used to accelerate ongoing commercialization of Lenire® tinnitus treatment device
NewsNeuromod Broadens Senior Leadership Team in Preparation for Global Commercialisation of Lenire™ Tinnitus Treatment
NewsNEUROMOD VIDEO: “New Treatment for Tinnitus Evaluated in over 500 Patients” [Dr. Hubert Lim presentation]
NewsAnother upcoming Neuromod Device podium abstract “from the future” (March 29, 2019) – with some interesting implications…
